| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 113 | 2024 | 1581 | 9.950 |
Why?
|
| Bone Density | 182 | 2024 | 3491 | 9.740 |
Why?
|
| Hip Fractures | 85 | 2024 | 996 | 8.630 |
Why?
|
| Osteoporotic Fractures | 42 | 2024 | 415 | 7.020 |
Why?
|
| Accidental Falls | 47 | 2023 | 1077 | 3.810 |
Why?
|
| Nursing Homes | 36 | 2023 | 1084 | 3.380 |
Why?
|
| Bone Density Conservation Agents | 26 | 2024 | 791 | 3.130 |
Why?
|
| Absorptiometry, Photon | 64 | 2024 | 1707 | 3.030 |
Why?
|
| Sarcopenia | 27 | 2024 | 378 | 2.950 |
Why?
|
| Fractures, Bone | 40 | 2024 | 2043 | 2.830 |
Why?
|
| Aorta, Abdominal | 23 | 2024 | 627 | 2.610 |
Why?
|
| Bone and Bones | 33 | 2024 | 2559 | 2.530 |
Why?
|
| Spinal Fractures | 26 | 2024 | 702 | 2.190 |
Why?
|
| Homes for the Aged | 20 | 2021 | 273 | 1.970 |
Why?
|
| Osteoporosis, Postmenopausal | 20 | 2019 | 399 | 1.890 |
Why?
|
| Hand Strength | 19 | 2021 | 466 | 1.790 |
Why?
|
| Aortic Diseases | 14 | 2023 | 741 | 1.650 |
Why?
|
| Aging | 46 | 2024 | 8728 | 1.620 |
Why?
|
| Genome-Wide Association Study | 69 | 2023 | 12808 | 1.600 |
Why?
|
| Muscle Strength | 14 | 2024 | 639 | 1.490 |
Why?
|
| Vibration | 6 | 2016 | 334 | 1.480 |
Why?
|
| Inheritance Patterns | 7 | 2018 | 345 | 1.460 |
Why?
|
| Aged, 80 and over | 190 | 2024 | 59548 | 1.450 |
Why?
|
| Vitamin D | 26 | 2018 | 3270 | 1.430 |
Why?
|
| Aged | 322 | 2024 | 171344 | 1.410 |
Why?
|
| Lumbar Vertebrae | 38 | 2023 | 1878 | 1.340 |
Why?
|
| Spine | 23 | 2021 | 1134 | 1.240 |
Why?
|
| Femur Neck | 23 | 2020 | 316 | 1.230 |
Why?
|
| Bone Diseases, Metabolic | 6 | 2023 | 407 | 1.230 |
Why?
|
| Diphosphonates | 10 | 2023 | 625 | 1.210 |
Why?
|
| Intra-Abdominal Fat | 4 | 2024 | 624 | 1.150 |
Why?
|
| Consensus | 11 | 2024 | 3208 | 1.110 |
Why?
|
| Polymorphism, Single Nucleotide | 58 | 2021 | 16044 | 1.090 |
Why?
|
| Alendronate | 11 | 2021 | 174 | 1.080 |
Why?
|
| Female | 370 | 2024 | 396532 | 1.050 |
Why?
|
| Thoracic Vertebrae | 14 | 2019 | 613 | 1.040 |
Why?
|
| Calcinosis | 15 | 2018 | 1480 | 1.040 |
Why?
|
| Genetic Loci | 14 | 2021 | 2631 | 1.020 |
Why?
|
| Humans | 481 | 2024 | 766812 | 1.010 |
Why?
|
| Geriatric Assessment | 12 | 2017 | 1422 | 0.990 |
Why?
|
| Male | 319 | 2024 | 364154 | 0.990 |
Why?
|
| Calcium, Dietary | 12 | 2018 | 527 | 0.940 |
Why?
|
| Frail Elderly | 12 | 2022 | 781 | 0.910 |
Why?
|
| Postural Balance | 11 | 2015 | 637 | 0.900 |
Why?
|
| Diet | 29 | 2024 | 8088 | 0.890 |
Why?
|
| Muscle Weakness | 9 | 2021 | 412 | 0.860 |
Why?
|
| Quantitative Trait Loci | 23 | 2020 | 2133 | 0.850 |
Why?
|
| Cohort Studies | 97 | 2024 | 41706 | 0.830 |
Why?
|
| Risk Factors | 123 | 2024 | 74889 | 0.780 |
Why?
|
| Methylmalonic Acid | 1 | 2021 | 50 | 0.760 |
Why?
|
| Musculoskeletal System | 4 | 2019 | 187 | 0.750 |
Why?
|
| Finite Element Analysis | 5 | 2018 | 441 | 0.740 |
Why?
|
| Dietary Proteins | 10 | 2017 | 960 | 0.720 |
Why?
|
| Vitamin B Complex | 2 | 2021 | 299 | 0.700 |
Why?
|
| Middle Aged | 193 | 2024 | 223267 | 0.700 |
Why?
|
| Protective Devices | 3 | 2010 | 72 | 0.700 |
Why?
|
| Longevity | 9 | 2024 | 1083 | 0.690 |
Why?
|
| Bone Remodeling | 6 | 2017 | 577 | 0.680 |
Why?
|
| Mobility Limitation | 9 | 2021 | 409 | 0.670 |
Why?
|
| Dietary Supplements | 17 | 2018 | 3429 | 0.670 |
Why?
|
| Mannose-Binding Lectin | 1 | 2020 | 146 | 0.670 |
Why?
|
| Dairy Products | 6 | 2022 | 490 | 0.660 |
Why?
|
| Hip | 9 | 2012 | 251 | 0.650 |
Why?
|
| Muscle, Skeletal | 14 | 2024 | 4968 | 0.650 |
Why?
|
| Independent Living | 10 | 2023 | 584 | 0.650 |
Why?
|
| Thinness | 4 | 2017 | 482 | 0.640 |
Why?
|
| Longitudinal Studies | 43 | 2024 | 14762 | 0.640 |
Why?
|
| Radius | 8 | 2024 | 441 | 0.630 |
Why?
|
| Activities of Daily Living | 16 | 2023 | 2429 | 0.630 |
Why?
|
| Equipment and Supplies | 2 | 2012 | 273 | 0.630 |
Why?
|
| Body Composition | 16 | 2020 | 2441 | 0.620 |
Why?
|
| Protective Clothing | 2 | 2010 | 103 | 0.610 |
Why?
|
| Genetic Predisposition to Disease | 28 | 2021 | 18076 | 0.600 |
Why?
|
| Risk Assessment | 28 | 2024 | 24299 | 0.590 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2019 | 792 | 0.590 |
Why?
|
| Calcaneus | 6 | 2022 | 144 | 0.590 |
Why?
|
| Femur | 18 | 2015 | 1318 | 0.580 |
Why?
|
| Tomography, X-Ray Computed | 31 | 2024 | 20710 | 0.560 |
Why?
|
| Advisory Committees | 2 | 2024 | 797 | 0.550 |
Why?
|
| Vitamin D Deficiency | 6 | 2017 | 1349 | 0.550 |
Why?
|
| DNA Methylation | 11 | 2023 | 4427 | 0.530 |
Why?
|
| Sex Characteristics | 13 | 2018 | 2645 | 0.530 |
Why?
|
| RANK Ligand | 3 | 2014 | 321 | 0.530 |
Why?
|
| Genome, Human | 13 | 2021 | 4443 | 0.520 |
Why?
|
| Pelvic Bones | 3 | 2019 | 274 | 0.510 |
Why?
|
| Genetic Variation | 9 | 2021 | 6613 | 0.510 |
Why?
|
| Critical Pathways | 1 | 2019 | 475 | 0.500 |
Why?
|
| Carotenoids | 5 | 2024 | 620 | 0.500 |
Why?
|
| Phenotype | 25 | 2024 | 16722 | 0.490 |
Why?
|
| Kyphosis | 5 | 2019 | 252 | 0.480 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 377 | 0.480 |
Why?
|
| Incidence | 35 | 2024 | 21527 | 0.480 |
Why?
|
| Vitamin B 12 | 3 | 2021 | 531 | 0.470 |
Why?
|
| Genetic Linkage | 9 | 2010 | 2342 | 0.470 |
Why?
|
| Vegetables | 6 | 2024 | 1199 | 0.460 |
Why?
|
| Mendelian Randomization Analysis | 7 | 2024 | 1044 | 0.460 |
Why?
|
| Sex Factors | 32 | 2021 | 10619 | 0.450 |
Why?
|
| Tibia | 8 | 2024 | 1071 | 0.450 |
Why?
|
| Dementia | 4 | 2024 | 2741 | 0.440 |
Why?
|
| GTPase-Activating Proteins | 1 | 2016 | 467 | 0.440 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2015 | 357 | 0.440 |
Why?
|
| Body Mass Index | 28 | 2024 | 13050 | 0.430 |
Why?
|
| Fruit | 6 | 2024 | 1166 | 0.430 |
Why?
|
| Muscles | 6 | 2023 | 1576 | 0.430 |
Why?
|
| Adult | 110 | 2024 | 223305 | 0.430 |
Why?
|
| Calibration | 2 | 2019 | 814 | 0.420 |
Why?
|
| Genomics | 7 | 2022 | 5922 | 0.420 |
Why?
|
| Vitamin K 1 | 4 | 2007 | 47 | 0.420 |
Why?
|
| Massachusetts | 29 | 2015 | 8890 | 0.410 |
Why?
|
| Testosterone | 9 | 2021 | 2495 | 0.410 |
Why?
|
| Estradiol | 7 | 2018 | 1947 | 0.410 |
Why?
|
| Medicare | 20 | 2023 | 6813 | 0.410 |
Why?
|
| Quantitative Trait, Heritable | 6 | 2018 | 540 | 0.410 |
Why?
|
| Gait | 8 | 2021 | 823 | 0.400 |
Why?
|
| Silicon | 3 | 2009 | 141 | 0.400 |
Why?
|
| Epigenesis, Genetic | 11 | 2023 | 3828 | 0.400 |
Why?
|
| Polymorphism, Genetic | 7 | 2014 | 4249 | 0.400 |
Why?
|
| Tai Ji | 3 | 2012 | 289 | 0.400 |
Why?
|
| Age Factors | 39 | 2020 | 18397 | 0.390 |
Why?
|
| Flavonols | 2 | 2023 | 84 | 0.390 |
Why?
|
| Long-Term Care | 5 | 2016 | 630 | 0.390 |
Why?
|
| Osteoprotegerin | 2 | 2014 | 179 | 0.390 |
Why?
|
| Patient Compliance | 6 | 2012 | 2694 | 0.390 |
Why?
|
| Calcium | 15 | 2022 | 5783 | 0.380 |
Why?
|
| Vitamin K | 4 | 2010 | 314 | 0.380 |
Why?
|
| Genotype | 23 | 2021 | 13036 | 0.370 |
Why?
|
| Homocysteine | 4 | 2013 | 638 | 0.370 |
Why?
|
| Atherosclerosis | 6 | 2022 | 3421 | 0.360 |
Why?
|
| Antihypertensive Agents | 3 | 2023 | 2030 | 0.360 |
Why?
|
| Postmenopause | 14 | 2019 | 2517 | 0.360 |
Why?
|
| Milk | 6 | 2022 | 436 | 0.360 |
Why?
|
| Genetic Pleiotropy | 4 | 2019 | 182 | 0.360 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2012 | 157 | 0.360 |
Why?
|
| Prospective Studies | 50 | 2024 | 54872 | 0.350 |
Why?
|
| Folic Acid | 3 | 2021 | 1337 | 0.350 |
Why?
|
| Linkage Disequilibrium | 10 | 2020 | 1996 | 0.340 |
Why?
|
| Cross-Sectional Studies | 43 | 2024 | 26309 | 0.340 |
Why?
|
| Proportional Hazards Models | 18 | 2020 | 12536 | 0.340 |
Why?
|
| LDL-Receptor Related Proteins | 2 | 2008 | 118 | 0.340 |
Why?
|
| Ascorbic Acid | 4 | 2023 | 658 | 0.340 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2013 | 557 | 0.330 |
Why?
|
| Disabled Persons | 5 | 2018 | 1209 | 0.330 |
Why?
|
| Research Design | 8 | 2024 | 6206 | 0.330 |
Why?
|
| Estrogen Replacement Therapy | 10 | 2014 | 1204 | 0.330 |
Why?
|
| Alcoholic Beverages | 2 | 2009 | 266 | 0.320 |
Why?
|
| Benzodiazepines | 1 | 2015 | 1137 | 0.320 |
Why?
|
| Skilled Nursing Facilities | 3 | 2023 | 406 | 0.320 |
Why?
|
| Bone Resorption | 6 | 2017 | 721 | 0.320 |
Why?
|
| United States | 51 | 2023 | 72945 | 0.310 |
Why?
|
| Bone Diseases | 1 | 2012 | 412 | 0.310 |
Why?
|
| Adipose Tissue | 7 | 2023 | 3317 | 0.310 |
Why?
|
| Cardiovascular Diseases | 12 | 2024 | 15652 | 0.310 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2023 | 1044 | 0.310 |
Why?
|
| Wnt Proteins | 3 | 2015 | 722 | 0.300 |
Why?
|
| Body Fluid Compartments | 2 | 2019 | 49 | 0.300 |
Why?
|
| Follow-Up Studies | 37 | 2023 | 39312 | 0.300 |
Why?
|
| Estrogens | 7 | 2014 | 1528 | 0.290 |
Why?
|
| Radiography | 25 | 2014 | 6968 | 0.280 |
Why?
|
| Resistance Training | 3 | 2021 | 197 | 0.280 |
Why?
|
| Body Height | 3 | 2012 | 1562 | 0.280 |
Why?
|
| Family Characteristics | 1 | 2012 | 1002 | 0.270 |
Why?
|
| Coronary Artery Disease | 6 | 2024 | 6575 | 0.270 |
Why?
|
| Reminder Systems | 1 | 2010 | 389 | 0.270 |
Why?
|
| Hand | 3 | 2017 | 910 | 0.270 |
Why?
|
| Receptors, Calcitriol | 2 | 2000 | 361 | 0.270 |
Why?
|
| Vascular Diseases | 3 | 2023 | 1161 | 0.270 |
Why?
|
| Menarche | 4 | 2018 | 532 | 0.260 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2002 | 1934 | 0.260 |
Why?
|
| Eating | 6 | 2022 | 1539 | 0.250 |
Why?
|
| Habits | 1 | 2006 | 148 | 0.250 |
Why?
|
| Carbonated Beverages | 1 | 2006 | 209 | 0.240 |
Why?
|
| Alcohol Drinking | 7 | 2009 | 4045 | 0.240 |
Why?
|
| Linear Models | 12 | 2021 | 5873 | 0.240 |
Why?
|
| Life Style | 5 | 2020 | 3926 | 0.240 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 5888 | 0.240 |
Why?
|
| Vitamins | 4 | 2023 | 1631 | 0.240 |
Why?
|
| Adiposity | 4 | 2023 | 1892 | 0.240 |
Why?
|
| Institutionalization | 2 | 1995 | 108 | 0.230 |
Why?
|
| Arteriosclerosis | 5 | 2002 | 1055 | 0.230 |
Why?
|
| Quadriceps Muscle | 2 | 2017 | 157 | 0.230 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2007 | 706 | 0.230 |
Why?
|
| Age Distribution | 9 | 2016 | 2869 | 0.230 |
Why?
|
| Confidence Intervals | 10 | 2016 | 2921 | 0.230 |
Why?
|
| Exercise | 7 | 2020 | 5945 | 0.230 |
Why?
|
| Alzheimer Disease | 7 | 2024 | 8715 | 0.220 |
Why?
|
| Premenopause | 4 | 2013 | 1039 | 0.220 |
Why?
|
| Body Size | 4 | 2012 | 461 | 0.220 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 117 | 0.220 |
Why?
|
| Mental Recall | 1 | 2010 | 1218 | 0.220 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2004 | 119 | 0.220 |
Why?
|
| CpG Islands | 5 | 2023 | 1208 | 0.220 |
Why?
|
| Retrospective Studies | 33 | 2024 | 81657 | 0.210 |
Why?
|
| Feeding Behavior | 6 | 2018 | 3208 | 0.210 |
Why?
|
| Smoking | 13 | 2016 | 9077 | 0.210 |
Why?
|
| Cause of Death | 5 | 2020 | 3717 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 2002 | 24 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2002 | 28 | 0.210 |
Why?
|
| Leukotriene B4 | 2 | 1996 | 281 | 0.200 |
Why?
|
| Quercetin | 1 | 2023 | 97 | 0.200 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 558 | 0.200 |
Why?
|
| Wounds and Injuries | 3 | 2014 | 2513 | 0.200 |
Why?
|
| Chromosome Mapping | 5 | 2020 | 4618 | 0.200 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 276 | 0.200 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2019 | 833 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2015 | 10745 | 0.200 |
Why?
|
| Cross-Over Studies | 3 | 2015 | 2105 | 0.200 |
Why?
|
| Interleukin-6 | 4 | 2022 | 3226 | 0.200 |
Why?
|
| Weight-Bearing | 3 | 2017 | 530 | 0.200 |
Why?
|
| Subcutaneous Fat | 2 | 2024 | 401 | 0.200 |
Why?
|
| Heat-Shock Proteins | 2 | 2019 | 792 | 0.200 |
Why?
|
| Risk | 8 | 2013 | 9602 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2010 | 2233 | 0.200 |
Why?
|
| Predictive Value of Tests | 10 | 2020 | 15425 | 0.200 |
Why?
|
| Principal Component Analysis | 2 | 2012 | 949 | 0.200 |
Why?
|
| Anorexia Nervosa | 2 | 2024 | 1328 | 0.200 |
Why?
|
| Least-Squares Analysis | 3 | 2017 | 368 | 0.200 |
Why?
|
| Boston | 8 | 2022 | 9346 | 0.190 |
Why?
|
| Manometry | 1 | 2024 | 458 | 0.190 |
Why?
|
| Self Report | 2 | 2013 | 3771 | 0.190 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3078 | 0.190 |
Why?
|
| Blood Vessels | 1 | 2007 | 1111 | 0.190 |
Why?
|
| Acceleration | 1 | 2022 | 189 | 0.190 |
Why?
|
| Hospitalization | 8 | 2023 | 10816 | 0.190 |
Why?
|
| Cholesterol | 3 | 2004 | 2904 | 0.190 |
Why?
|
| Gene Regulatory Networks | 5 | 2024 | 1752 | 0.190 |
Why?
|
| Versicans | 2 | 2019 | 40 | 0.190 |
Why?
|
| Spinal Curvatures | 2 | 2016 | 74 | 0.190 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2020 | 170 | 0.190 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 2334 | 0.180 |
Why?
|
| Time Factors | 18 | 2020 | 40149 | 0.180 |
Why?
|
| Diet Surveys | 6 | 2022 | 1159 | 0.180 |
Why?
|
| Ultrasonography | 11 | 2022 | 5990 | 0.180 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2021 | 135 | 0.180 |
Why?
|
| Obesity | 10 | 2024 | 13090 | 0.180 |
Why?
|
| Observer Variation | 7 | 2011 | 2614 | 0.180 |
Why?
|
| Alleles | 10 | 2014 | 6896 | 0.180 |
Why?
|
| Calcifediol | 2 | 2016 | 156 | 0.180 |
Why?
|
| Acid-Base Equilibrium | 1 | 2001 | 180 | 0.180 |
Why?
|
| Elder Nutritional Physiological Phenomena | 1 | 2020 | 7 | 0.180 |
Why?
|
| Brassicaceae | 1 | 2020 | 10 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6514 | 0.180 |
Why?
|
| Brassica | 1 | 2020 | 39 | 0.180 |
Why?
|
| Meta-Analysis as Topic | 5 | 2019 | 1365 | 0.180 |
Why?
|
| Multivariate Analysis | 14 | 2019 | 12064 | 0.170 |
Why?
|
| Vitamin K Deficiency | 1 | 2000 | 24 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 640 | 0.170 |
Why?
|
| Apolipoproteins E | 4 | 2014 | 1459 | 0.170 |
Why?
|
| Vitamin B 6 | 1 | 2021 | 237 | 0.170 |
Why?
|
| Magnesium | 3 | 2002 | 815 | 0.170 |
Why?
|
| Regression Analysis | 12 | 2018 | 6329 | 0.170 |
Why?
|
| Analysis of Variance | 7 | 2010 | 6214 | 0.170 |
Why?
|
| Logistic Models | 13 | 2022 | 13276 | 0.170 |
Why?
|
| Hip Joint | 5 | 2012 | 1017 | 0.170 |
Why?
|
| Blood Cells | 2 | 2022 | 309 | 0.170 |
Why?
|
| Osteocalcin | 3 | 2006 | 271 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 10384 | 0.160 |
Why?
|
| Caffeine | 3 | 2014 | 702 | 0.160 |
Why?
|
| Musculoskeletal Diseases | 2 | 2024 | 598 | 0.160 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 325 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2000 | 432 | 0.160 |
Why?
|
| Odds Ratio | 17 | 2022 | 9661 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 2903 | 0.160 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 2019 | 31 | 0.160 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 168 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 12246 | 0.160 |
Why?
|
| Apolipoprotein E2 | 1 | 2019 | 134 | 0.160 |
Why?
|
| Haplotypes | 5 | 2021 | 2726 | 0.160 |
Why?
|
| Access to Information | 1 | 2022 | 317 | 0.150 |
Why?
|
| Animals | 33 | 2024 | 168939 | 0.150 |
Why?
|
| Reproducibility of Results | 16 | 2019 | 20146 | 0.150 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2012 | 539 | 0.150 |
Why?
|
| Apolipoprotein E4 | 2 | 2019 | 709 | 0.150 |
Why?
|
| Teriparatide | 3 | 2021 | 225 | 0.150 |
Why?
|
| Body Weight | 6 | 2023 | 4626 | 0.150 |
Why?
|
| Organ Size | 7 | 2018 | 2262 | 0.150 |
Why?
|
| Fracture Fixation | 1 | 2020 | 370 | 0.150 |
Why?
|
| Soft Tissue Injuries | 1 | 2019 | 173 | 0.150 |
Why?
|
| Troponin I | 1 | 2022 | 659 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2011 | 3459 | 0.150 |
Why?
|
| Double-Blind Method | 13 | 2024 | 12430 | 0.150 |
Why?
|
| Australia | 4 | 2023 | 1263 | 0.150 |
Why?
|
| Sex Distribution | 6 | 2010 | 2274 | 0.150 |
Why?
|
| Musculoskeletal Development | 1 | 2017 | 14 | 0.150 |
Why?
|
| Mortality | 6 | 2021 | 2908 | 0.140 |
Why?
|
| Aromatase | 1 | 2018 | 147 | 0.140 |
Why?
|
| Dietary Fiber | 2 | 2021 | 767 | 0.140 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2017 | 58 | 0.140 |
Why?
|
| Back Pain | 3 | 2006 | 547 | 0.140 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2017 | 88 | 0.140 |
Why?
|
| Prevalence | 10 | 2020 | 15835 | 0.140 |
Why?
|
| Motor Activity | 5 | 2015 | 2711 | 0.140 |
Why?
|
| Amidohydrolases | 1 | 2018 | 160 | 0.140 |
Why?
|
| Excitatory Amino Acid Transporter 1 | 1 | 2016 | 18 | 0.140 |
Why?
|
| Nutrition Disorders | 1 | 1997 | 203 | 0.140 |
Why?
|
| Isosorbide Dinitrate | 1 | 2016 | 34 | 0.140 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 5182 | 0.140 |
Why?
|
| Estrone | 2 | 2018 | 234 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2017 | 313 | 0.130 |
Why?
|
| Receptor, EphB2 | 1 | 2016 | 31 | 0.130 |
Why?
|
| Femur Head | 1 | 2018 | 297 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2017 | 248 | 0.130 |
Why?
|
| Minerals | 2 | 2023 | 278 | 0.130 |
Why?
|
| Goals | 2 | 2024 | 717 | 0.130 |
Why?
|
| Young Adult | 14 | 2024 | 59939 | 0.130 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2017 | 183 | 0.130 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 766 | 0.130 |
Why?
|
| Phospholipase D | 1 | 1996 | 71 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 5795 | 0.130 |
Why?
|
| Electric Impedance | 2 | 2019 | 791 | 0.130 |
Why?
|
| Zygapophyseal Joint | 1 | 2018 | 129 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2010 | 3230 | 0.130 |
Why?
|
| Menopause | 4 | 2018 | 1656 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 3 | 2014 | 1080 | 0.130 |
Why?
|
| Oxandrolone | 1 | 2015 | 24 | 0.130 |
Why?
|
| Europe | 6 | 2021 | 3430 | 0.130 |
Why?
|
| Tooth Loss | 1 | 1998 | 198 | 0.130 |
Why?
|
| Fractures, Spontaneous | 3 | 2007 | 230 | 0.130 |
Why?
|
| Microsatellite Repeats | 3 | 2003 | 784 | 0.130 |
Why?
|
| Office Visits | 1 | 2000 | 593 | 0.130 |
Why?
|
| Osteoarthritis, Knee | 4 | 2007 | 1251 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2021 | 1241 | 0.130 |
Why?
|
| Tooth | 1 | 1997 | 210 | 0.130 |
Why?
|
| Disability Evaluation | 4 | 2020 | 1828 | 0.130 |
Why?
|
| Comorbidity | 8 | 2019 | 10580 | 0.130 |
Why?
|
| Posture | 2 | 2010 | 955 | 0.130 |
Why?
|
| Lod Score | 3 | 2012 | 600 | 0.130 |
Why?
|
| Cholecalciferol | 2 | 2011 | 550 | 0.130 |
Why?
|
| Twins | 1 | 2017 | 341 | 0.130 |
Why?
|
| Walking | 3 | 2021 | 1201 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2022 | 746 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 2252 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2022 | 3789 | 0.120 |
Why?
|
| Physical Exertion | 1 | 1998 | 667 | 0.120 |
Why?
|
| Gene Frequency | 3 | 2017 | 3624 | 0.120 |
Why?
|
| Nitroglycerin | 1 | 2016 | 332 | 0.120 |
Why?
|
| Multifactorial Inheritance | 2 | 2020 | 1425 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2013 | 370 | 0.120 |
Why?
|
| Procollagen | 1 | 2015 | 189 | 0.120 |
Why?
|
| Potassium | 1 | 1999 | 1314 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2022 | 1404 | 0.120 |
Why?
|
| Geriatrics | 3 | 2019 | 394 | 0.120 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 1026 | 0.120 |
Why?
|
| Leukocytes | 3 | 2018 | 2034 | 0.110 |
Why?
|
| Life Expectancy | 3 | 2019 | 1248 | 0.110 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 2 | 2012 | 77 | 0.110 |
Why?
|
| Geography | 1 | 2016 | 651 | 0.110 |
Why?
|
| Pneumonia | 2 | 2020 | 2161 | 0.110 |
Why?
|
| Aortography | 1 | 2015 | 423 | 0.110 |
Why?
|
| Weight Loss | 3 | 2023 | 2712 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2024 | 4188 | 0.110 |
Why?
|
| Extremities | 2 | 2017 | 869 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2014 | 286 | 0.110 |
Why?
|
| Case-Control Studies | 13 | 2020 | 22248 | 0.110 |
Why?
|
| Genes, Y-Linked | 1 | 2013 | 12 | 0.110 |
Why?
|
| Forecasting | 2 | 2013 | 2936 | 0.110 |
Why?
|
| Knee Joint | 3 | 2007 | 1682 | 0.110 |
Why?
|
| Research Report | 1 | 2016 | 367 | 0.110 |
Why?
|
| Epigenomics | 1 | 2019 | 958 | 0.110 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 677 | 0.110 |
Why?
|
| Reference Standards | 1 | 2016 | 1010 | 0.110 |
Why?
|
| Exercise Therapy | 4 | 2012 | 935 | 0.100 |
Why?
|
| Placebos | 2 | 2015 | 1659 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2024 | 65286 | 0.100 |
Why?
|
| Anabolic Agents | 1 | 2015 | 256 | 0.100 |
Why?
|
| Yogurt | 1 | 2013 | 71 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 418 | 0.100 |
Why?
|
| Coronary Disease | 4 | 2009 | 5915 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2018 | 706 | 0.100 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 430 | 0.100 |
Why?
|
| Overweight | 1 | 2024 | 2447 | 0.100 |
Why?
|
| Telomerase | 1 | 2018 | 750 | 0.100 |
Why?
|
| Integrin alpha1 | 1 | 2012 | 13 | 0.100 |
Why?
|
| Multiple Sclerosis | 2 | 2018 | 3229 | 0.100 |
Why?
|
| Genes | 2 | 2013 | 1824 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2014 | 341 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2017 | 943 | 0.100 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2012 | 13 | 0.100 |
Why?
|
| Adolescent | 12 | 2024 | 88902 | 0.100 |
Why?
|
| Mass Screening | 3 | 2020 | 5454 | 0.100 |
Why?
|
| GATA Transcription Factors | 1 | 2012 | 28 | 0.100 |
Why?
|
| Brachial Artery | 2 | 2024 | 373 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 988 | 0.100 |
Why?
|
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2012 | 33 | 0.100 |
Why?
|
| Diuretics | 2 | 2012 | 614 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 713 | 0.100 |
Why?
|
| Seafood | 2 | 2015 | 395 | 0.100 |
Why?
|
| Collagen Type I | 1 | 2015 | 616 | 0.100 |
Why?
|
| Fishes | 2 | 2015 | 607 | 0.100 |
Why?
|
| Sensation Disorders | 1 | 2012 | 160 | 0.100 |
Why?
|
| Genetic Association Studies | 3 | 2016 | 2744 | 0.100 |
Why?
|
| Carrier Proteins | 2 | 2017 | 4926 | 0.100 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 3692 | 0.090 |
Why?
|
| Methyltransferases | 1 | 2014 | 373 | 0.090 |
Why?
|
| Mice | 13 | 2024 | 81898 | 0.090 |
Why?
|
| Benzothiadiazines | 1 | 1991 | 31 | 0.090 |
Why?
|
| France | 1 | 2012 | 496 | 0.090 |
Why?
|
| Immunity | 2 | 2019 | 1002 | 0.090 |
Why?
|
| Genetic Markers | 4 | 2016 | 2603 | 0.090 |
Why?
|
| Analgesics | 1 | 2017 | 1068 | 0.090 |
Why?
|
| Phosphate Transport Proteins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 15912 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 7430 | 0.090 |
Why?
|
| alpha-Linolenic Acid | 1 | 2011 | 145 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3796 | 0.090 |
Why?
|
| Phosphatidylcholines | 1 | 2012 | 404 | 0.090 |
Why?
|
| Refusal to Participate | 1 | 2010 | 30 | 0.090 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 2429 | 0.090 |
Why?
|
| Acids | 1 | 2011 | 125 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 2011 | 186 | 0.090 |
Why?
|
| Societies, Scientific | 1 | 2011 | 221 | 0.090 |
Why?
|
| Memantine | 1 | 2011 | 110 | 0.090 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2011 | 240 | 0.090 |
Why?
|
| Quebec | 2 | 2007 | 140 | 0.090 |
Why?
|
| Gene Expression Regulation | 8 | 2019 | 11924 | 0.090 |
Why?
|
| Osteoarthritis | 1 | 2018 | 1072 | 0.090 |
Why?
|
| Administration, Oral | 6 | 2023 | 4019 | 0.090 |
Why?
|
| Nootropic Agents | 1 | 2011 | 159 | 0.090 |
Why?
|
| Drinking | 1 | 2011 | 196 | 0.080 |
Why?
|
| Patient Selection | 5 | 2010 | 4252 | 0.080 |
Why?
|
| Pyrophosphatases | 1 | 2010 | 142 | 0.080 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 222 | 0.080 |
Why?
|
| Metacarpus | 4 | 2004 | 37 | 0.080 |
Why?
|
| Calcification, Physiologic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2014 | 1657 | 0.080 |
Why?
|
| Disease Management | 1 | 2020 | 2533 | 0.080 |
Why?
|
| Terminal Care | 1 | 2021 | 1769 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2011 | 242 | 0.080 |
Why?
|
| Reference Values | 4 | 2024 | 4914 | 0.080 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2010 | 205 | 0.080 |
Why?
|
| Membrane Proteins | 5 | 2017 | 7869 | 0.080 |
Why?
|
| Protective Agents | 1 | 2010 | 150 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2002 | 3266 | 0.080 |
Why?
|
| Child | 9 | 2021 | 80670 | 0.080 |
Why?
|
| Family | 2 | 2018 | 3209 | 0.080 |
Why?
|
| Outpatients | 1 | 2017 | 1596 | 0.080 |
Why?
|
| Coronary Vessels | 3 | 2024 | 3115 | 0.080 |
Why?
|
| C-Reactive Protein | 3 | 2022 | 3853 | 0.080 |
Why?
|
| Hallux Valgus | 1 | 2009 | 67 | 0.080 |
Why?
|
| Obesity, Abdominal | 2 | 2023 | 372 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 2535 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 581 | 0.080 |
Why?
|
| Beer | 1 | 2009 | 135 | 0.080 |
Why?
|
| Thyrotropin | 2 | 2012 | 834 | 0.080 |
Why?
|
| DNA Copy Number Variations | 3 | 2013 | 2045 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 1733 | 0.080 |
Why?
|
| Rehabilitation Centers | 1 | 2010 | 249 | 0.080 |
Why?
|
| Health | 1 | 2011 | 396 | 0.080 |
Why?
|
| Osteogenesis | 2 | 2013 | 1282 | 0.080 |
Why?
|
| Medical Audit | 1 | 2010 | 454 | 0.080 |
Why?
|
| Educational Status | 4 | 2009 | 2510 | 0.080 |
Why?
|
| Calcitonin | 2 | 2018 | 327 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2013 | 811 | 0.080 |
Why?
|
| Wine | 1 | 2009 | 172 | 0.080 |
Why?
|
| Health Services for the Aged | 1 | 1991 | 264 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2022 | 12795 | 0.080 |
Why?
|
| Recurrence | 3 | 2012 | 8507 | 0.080 |
Why?
|
| Syncope | 1 | 2011 | 431 | 0.080 |
Why?
|
| Medication Adherence | 2 | 2010 | 2190 | 0.080 |
Why?
|
| Accidents | 1 | 1989 | 164 | 0.080 |
Why?
|
| Amides | 1 | 1991 | 451 | 0.070 |
Why?
|
| Interviews as Topic | 3 | 2012 | 2741 | 0.070 |
Why?
|
| Clodronic Acid | 1 | 2008 | 60 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 8928 | 0.070 |
Why?
|
| Cognition | 4 | 2018 | 7057 | 0.070 |
Why?
|
| Heterozygote | 4 | 2021 | 2795 | 0.070 |
Why?
|
| Metacarpal Bones | 1 | 2008 | 77 | 0.070 |
Why?
|
| Cells, Cultured | 6 | 2021 | 18986 | 0.070 |
Why?
|
| Pressure Ulcer | 1 | 2009 | 158 | 0.070 |
Why?
|
| Ethanol | 2 | 2009 | 1326 | 0.070 |
Why?
|
| Nutrition Assessment | 3 | 2016 | 739 | 0.070 |
Why?
|
| Growth Hormone | 3 | 2001 | 572 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2015 | 1029 | 0.070 |
Why?
|
| Nutritional Status | 5 | 2013 | 1621 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2018 | 1543 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 285 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2009 | 534 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2015 | 3591 | 0.070 |
Why?
|
| Rhode Island | 4 | 1998 | 351 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 1768 | 0.070 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 855 | 0.070 |
Why?
|
| Public Health | 2 | 2019 | 2680 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 1627 | 0.070 |
Why?
|
| Energy Intake | 4 | 2020 | 2142 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2011 | 1494 | 0.070 |
Why?
|
| Stroke | 3 | 2023 | 9744 | 0.070 |
Why?
|
| Health Surveys | 3 | 2020 | 4055 | 0.070 |
Why?
|
| Movement | 2 | 2012 | 1468 | 0.070 |
Why?
|
| Standard of Care | 1 | 2011 | 569 | 0.070 |
Why?
|
| Telephone | 1 | 2010 | 629 | 0.070 |
Why?
|
| Potassium, Dietary | 2 | 2009 | 103 | 0.070 |
Why?
|
| Pedigree | 5 | 2007 | 4539 | 0.070 |
Why?
|
| Etidronic Acid | 1 | 2006 | 63 | 0.070 |
Why?
|
| Meat | 2 | 2015 | 588 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2010 | 442 | 0.060 |
Why?
|
| Phosphoproteins | 2 | 2012 | 2448 | 0.060 |
Why?
|
| Exostoses | 1 | 2006 | 30 | 0.060 |
Why?
|
| Algorithms | 6 | 2016 | 14073 | 0.060 |
Why?
|
| Materials Testing | 1 | 2009 | 870 | 0.060 |
Why?
|
| Urine | 1 | 1987 | 363 | 0.060 |
Why?
|
| Environment | 1 | 2012 | 1120 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2014 | 2493 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 1150 | 0.060 |
Why?
|
| Pharyngeal Muscles | 1 | 1986 | 81 | 0.060 |
Why?
|
| Arthralgia | 1 | 2009 | 459 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 2255 | 0.060 |
Why?
|
| Mental Status Schedule | 2 | 2005 | 315 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2008 | 484 | 0.060 |
Why?
|
| Intermittent Claudication | 1 | 2008 | 305 | 0.060 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 344 | 0.060 |
Why?
|
| Warfarin | 1 | 2014 | 1493 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2012 | 735 | 0.060 |
Why?
|
| Intelligence | 1 | 2010 | 925 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 4349 | 0.060 |
Why?
|
| Hypertension | 2 | 2023 | 8616 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2014 | 553 | 0.060 |
Why?
|
| Age Determination by Skeleton | 1 | 2005 | 124 | 0.060 |
Why?
|
| Morbidity | 3 | 2023 | 1754 | 0.060 |
Why?
|
| New Hampshire | 2 | 2018 | 174 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 1991 | 1417 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 6066 | 0.060 |
Why?
|
| Internal Medicine | 1 | 1991 | 1064 | 0.060 |
Why?
|
| Metabolome | 1 | 2011 | 1008 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2010 | 1438 | 0.060 |
Why?
|
| Survival Rate | 4 | 2018 | 12826 | 0.060 |
Why?
|
| Thiazides | 1 | 2023 | 19 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2023 | 4854 | 0.060 |
Why?
|
| Leg | 1 | 2009 | 1087 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3411 | 0.060 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 5795 | 0.060 |
Why?
|
| Molecular Sequence Annotation | 2 | 2016 | 526 | 0.060 |
Why?
|
| Chromatography, Liquid | 2 | 2021 | 996 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2008 | 2594 | 0.050 |
Why?
|
| Amlodipine | 1 | 2023 | 84 | 0.050 |
Why?
|
| Muscular Dystrophies | 1 | 1986 | 393 | 0.050 |
Why?
|
| Osteoblasts | 2 | 2021 | 1144 | 0.050 |
Why?
|
| Peptides | 1 | 2015 | 4347 | 0.050 |
Why?
|
| Acute Disease | 2 | 2012 | 7240 | 0.050 |
Why?
|
| Chromosomes, Human, X | 2 | 2018 | 319 | 0.050 |
Why?
|
| Depression | 1 | 2023 | 8225 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2023 | 80 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2003 | 171 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2021 | 42577 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2016 | 2817 | 0.050 |
Why?
|
| Bread | 1 | 2002 | 23 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3110 | 0.050 |
Why?
|
| Osteoclasts | 2 | 2021 | 713 | 0.050 |
Why?
|
| Candy | 1 | 2002 | 36 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 1989 | 1814 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2015 | 5143 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3232 | 0.050 |
Why?
|
| DNA Repair | 1 | 2012 | 2050 | 0.050 |
Why?
|
| Heart | 1 | 2015 | 4425 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2008 | 1075 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 1514 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2021 | 2978 | 0.050 |
Why?
|
| Safety Management | 1 | 2008 | 765 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 14653 | 0.050 |
Why?
|
| Heart Failure | 2 | 2023 | 11879 | 0.050 |
Why?
|
| Sampling Studies | 2 | 2012 | 614 | 0.050 |
Why?
|
| Disease Progression | 4 | 2024 | 13642 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2004 | 411 | 0.050 |
Why?
|
| Vision Disorders | 1 | 1989 | 1090 | 0.050 |
Why?
|
| Restraint, Physical | 2 | 1995 | 184 | 0.050 |
Why?
|
| Oculomotor Muscles | 1 | 1986 | 405 | 0.050 |
Why?
|
| Urban Population | 1 | 2010 | 2040 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2023 | 220 | 0.050 |
Why?
|
| Epidemiologic Methods | 3 | 2012 | 1326 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2008 | 1170 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 9528 | 0.050 |
Why?
|
| Receptors, Glucagon | 1 | 2001 | 90 | 0.050 |
Why?
|
| South America | 1 | 2021 | 180 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2021 | 1198 | 0.050 |
Why?
|
| Hydrazones | 1 | 2001 | 105 | 0.050 |
Why?
|
| Disease Susceptibility | 3 | 2014 | 1791 | 0.050 |
Why?
|
| Pyrroles | 1 | 2007 | 1121 | 0.050 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2021 | 37 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2024 | 543 | 0.050 |
Why?
|
| Schools | 1 | 2010 | 1496 | 0.050 |
Why?
|
| Weight Lifting | 1 | 2001 | 130 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2024 | 1587 | 0.040 |
Why?
|
| Lumbosacral Region | 2 | 2000 | 294 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 108 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2008 | 2001 | 0.040 |
Why?
|
| Equipment Design | 2 | 2009 | 3488 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1604 | 0.040 |
Why?
|
| Heel | 1 | 2020 | 38 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 5536 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 193 | 0.040 |
Why?
|
| Parents | 1 | 2014 | 3592 | 0.040 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 1145 | 0.040 |
Why?
|
| Prognosis | 6 | 2021 | 29959 | 0.040 |
Why?
|
| Inflammation | 3 | 2023 | 10863 | 0.040 |
Why?
|
| Lung | 2 | 2017 | 10068 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2007 | 872 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2021 | 275 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2020 | 9358 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 7612 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2021 | 266 | 0.040 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 40 | 0.040 |
Why?
|
| Residence Characteristics | 3 | 2021 | 2116 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2021 | 14473 | 0.040 |
Why?
|
| Deglutition Disorders | 1 | 1986 | 640 | 0.040 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 9613 | 0.040 |
Why?
|
| Flavonoids | 1 | 2023 | 447 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2024 | 892 | 0.040 |
Why?
|
| Asia | 1 | 2021 | 629 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2011 | 412 | 0.040 |
Why?
|
| Triglycerides | 2 | 2004 | 2441 | 0.040 |
Why?
|
| Anemia | 1 | 2009 | 1514 | 0.040 |
Why?
|
| Databases, Genetic | 2 | 2020 | 1756 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 2001 | 1141 | 0.040 |
Why?
|
| Low Back Pain | 2 | 1998 | 986 | 0.040 |
Why?
|
| Psychomotor Performance | 2 | 1998 | 1885 | 0.040 |
Why?
|
| Maryland | 1 | 2019 | 277 | 0.040 |
Why?
|
| Vitamin E | 1 | 2023 | 872 | 0.040 |
Why?
|
| Fish Oils | 2 | 2014 | 483 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2021 | 702 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2002 | 289 | 0.040 |
Why?
|
| Quality of Life | 4 | 2019 | 13476 | 0.040 |
Why?
|
| Nitrogen | 1 | 2020 | 344 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 10101 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 4523 | 0.040 |
Why?
|
| Twin Studies as Topic | 1 | 2018 | 103 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 6965 | 0.040 |
Why?
|
| Cell Differentiation | 4 | 2021 | 11657 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2019 | 131 | 0.040 |
Why?
|
| Ossification, Heterotopic | 1 | 2001 | 240 | 0.040 |
Why?
|
| Propensity Score | 2 | 2018 | 1972 | 0.040 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11514 | 0.040 |
Why?
|
| Health Status | 3 | 2013 | 4087 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 1998 | 861 | 0.040 |
Why?
|
| Bicuspid | 1 | 1998 | 69 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2020 | 5092 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 834 | 0.040 |
Why?
|
| Cuspid | 1 | 1998 | 53 | 0.040 |
Why?
|
| Curriculum | 1 | 1991 | 3783 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4853 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 1729 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2024 | 1320 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 1991 | 3927 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 844 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2002 | 896 | 0.040 |
Why?
|
| Troponin T | 1 | 2022 | 786 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2017 | 134 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2000 | 3431 | 0.040 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2017 | 21 | 0.040 |
Why?
|
| Jaw, Edentulous | 1 | 1998 | 94 | 0.040 |
Why?
|
| Seasons | 3 | 2010 | 1519 | 0.030 |
Why?
|
| Molar | 1 | 1998 | 150 | 0.030 |
Why?
|
| Liver | 4 | 2021 | 7571 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2011 | 3967 | 0.030 |
Why?
|
| Supine Position | 1 | 2017 | 208 | 0.030 |
Why?
|
| Quinacrine | 1 | 1996 | 24 | 0.030 |
Why?
|
| Incisor | 1 | 1998 | 170 | 0.030 |
Why?
|
| Physical Education and Training | 1 | 1997 | 102 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2021 | 1228 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2004 | 1407 | 0.030 |
Why?
|
| Bed Rest | 1 | 2016 | 82 | 0.030 |
Why?
|
| DNA | 2 | 2000 | 7210 | 0.030 |
Why?
|
| Interleukins | 1 | 2021 | 796 | 0.030 |
Why?
|
| DNA Primers | 1 | 2000 | 2826 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2018 | 8065 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2019 | 818 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 861 | 0.030 |
Why?
|
| Western Australia | 1 | 2015 | 41 | 0.030 |
Why?
|
| RNA-Binding Proteins | 2 | 2019 | 1885 | 0.030 |
Why?
|
| Benzamides | 1 | 2001 | 1375 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2022 | 1540 | 0.030 |
Why?
|
| Indians, North American | 1 | 2019 | 354 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2021 | 962 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2005 | 2926 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2012 | 12159 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2016 | 514 | 0.030 |
Why?
|
| Stress, Mechanical | 2 | 2011 | 1674 | 0.030 |
Why?
|
| Pressure | 1 | 2018 | 1172 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2018 | 335 | 0.030 |
Why?
|
| Models, Economic | 1 | 2019 | 719 | 0.030 |
Why?
|
| Calcium Citrate | 1 | 2014 | 8 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2015 | 172 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 17532 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 787 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1622 | 0.030 |
Why?
|
| Personnel Selection | 1 | 1996 | 201 | 0.030 |
Why?
|
| Kentucky | 1 | 1994 | 83 | 0.030 |
Why?
|
| Missouri | 1 | 1994 | 113 | 0.030 |
Why?
|
| Tennessee | 1 | 1994 | 123 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 22351 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2008 | 3001 | 0.030 |
Why?
|
| Leadership | 1 | 2024 | 1394 | 0.030 |
Why?
|
| Receptors, Kainic Acid | 1 | 2014 | 91 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2000 | 802 | 0.030 |
Why?
|
| Receptors, GABA-B | 1 | 2014 | 59 | 0.030 |
Why?
|
| Alveolar Bone Loss | 1 | 1998 | 394 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2039 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 857 | 0.030 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2014 | 57 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2014 | 164 | 0.030 |
Why?
|
| Cadaver | 1 | 2018 | 1362 | 0.030 |
Why?
|
| Knee | 1 | 2015 | 274 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2013 | 93 | 0.030 |
Why?
|
| Adipocytes | 1 | 2021 | 1196 | 0.030 |
Why?
|
| Repressor Proteins | 2 | 2017 | 2979 | 0.030 |
Why?
|
| Fluoroimmunoassay | 1 | 2013 | 30 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 8045 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2014 | 229 | 0.030 |
Why?
|
| Exons | 1 | 2019 | 2392 | 0.030 |
Why?
|
| Physicians | 1 | 1991 | 4591 | 0.030 |
Why?
|
| Androgens | 1 | 2021 | 1280 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 857 | 0.030 |
Why?
|
| Dehydroepiandrosterone | 1 | 2014 | 249 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 1995 | 246 | 0.030 |
Why?
|
| Models, Biological | 2 | 2001 | 9464 | 0.030 |
Why?
|
| Chickens | 1 | 2015 | 843 | 0.030 |
Why?
|
| Myoblasts | 1 | 2014 | 234 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2022 | 2060 | 0.030 |
Why?
|
| Length of Stay | 1 | 2007 | 6491 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 1998 | 845 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1366 | 0.030 |
Why?
|
| Data Collection | 3 | 2006 | 3321 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3250 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 2014 | 326 | 0.030 |
Why?
|
| Zebrafish | 1 | 2024 | 3035 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 1691 | 0.020 |
Why?
|
| Risk Management | 1 | 1995 | 558 | 0.020 |
Why?
|
| Weight Gain | 1 | 2002 | 2356 | 0.020 |
Why?
|
| Self-Evaluation Programs | 1 | 1991 | 29 | 0.020 |
Why?
|
| Cytokines | 1 | 2007 | 7438 | 0.020 |
Why?
|
| Community Health Services | 1 | 1997 | 659 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 358 | 0.020 |
Why?
|
| Patient Participation | 1 | 2021 | 1445 | 0.020 |
Why?
|
| Gene Expression | 2 | 2017 | 7585 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9244 | 0.020 |
Why?
|
| Spectrin | 1 | 2012 | 176 | 0.020 |
Why?
|
| Software | 2 | 2016 | 4464 | 0.020 |
Why?
|
| Muscle Development | 1 | 2013 | 258 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 1027 | 0.020 |
Why?
|
| Telomere | 1 | 2018 | 943 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2004 | 3485 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 2011 | 0.020 |
Why?
|
| Wrist Injuries | 1 | 2014 | 215 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 1226 | 0.020 |
Why?
|
| DNA Primase | 1 | 2012 | 110 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2023 | 3464 | 0.020 |
Why?
|
| Metabolomics | 1 | 2021 | 1674 | 0.020 |
Why?
|
| Chromosomes, Mammalian | 1 | 2012 | 148 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1991 | 5943 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 4780 | 0.020 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2011 | 61 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 23618 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 1991 | 175 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 418 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2015 | 698 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 751 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2000 | 3446 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 1991 | 238 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2012 | 191 | 0.020 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 1991 | 93 | 0.020 |
Why?
|
| China | 1 | 2016 | 2386 | 0.020 |
Why?
|
| Accidents, Home | 1 | 2010 | 73 | 0.020 |
Why?
|
| Sulfotransferases | 1 | 2011 | 150 | 0.020 |
Why?
|
| Cell Count | 1 | 2014 | 1826 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2014 | 702 | 0.020 |
Why?
|
| Markov Chains | 1 | 2013 | 974 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 342 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 3408 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 246 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 246 | 0.020 |
Why?
|
| Actins | 1 | 2017 | 2061 | 0.020 |
Why?
|
| Computational Biology | 2 | 2012 | 3564 | 0.020 |
Why?
|
| Ovary | 1 | 2014 | 963 | 0.020 |
Why?
|
| Luminescent Measurements | 2 | 2008 | 342 | 0.020 |
Why?
|
| Physicians, Family | 1 | 1991 | 348 | 0.020 |
Why?
|
| Endonucleases | 1 | 2012 | 371 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 294 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2020 | 3138 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2350 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2013 | 1211 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2015 | 872 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 378 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2014 | 996 | 0.020 |
Why?
|
| Shoes | 1 | 2009 | 91 | 0.020 |
Why?
|
| Netherlands | 1 | 2014 | 2277 | 0.020 |
Why?
|
| Biopsy | 2 | 2016 | 6779 | 0.020 |
Why?
|
| Cell Death | 1 | 2014 | 1676 | 0.020 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 481 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2011 | 425 | 0.020 |
Why?
|
| Flatfoot | 1 | 2009 | 60 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2010 | 479 | 0.020 |
Why?
|
| Family Health | 1 | 2013 | 1254 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1814 | 0.020 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2013 | 540 | 0.020 |
Why?
|
| Proteins | 2 | 2014 | 6002 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1612 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2011 | 505 | 0.020 |
Why?
|
| Research | 1 | 1996 | 1977 | 0.020 |
Why?
|
| Thyroxine | 1 | 2012 | 665 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2014 | 1188 | 0.020 |
Why?
|
| Stem Cells | 1 | 2021 | 3536 | 0.020 |
Why?
|
| Glycosuria | 1 | 1987 | 44 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 800 | 0.020 |
Why?
|
| Exercise Test | 1 | 2015 | 2188 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2010 | 642 | 0.020 |
Why?
|
| Pyuria | 1 | 1987 | 30 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2011 | 497 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2023 | 8533 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 2009 | 256 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 451 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2018 | 4166 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 915 | 0.020 |
Why?
|
| Physicians' Offices | 1 | 1987 | 60 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2008 | 504 | 0.020 |
Why?
|
| Nitrites | 1 | 1987 | 156 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2000 | 6258 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2846 | 0.020 |
Why?
|
| Pulmonary Alveoli | 2 | 1987 | 665 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2011 | 565 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Health Services Research | 1 | 1994 | 1811 | 0.020 |
Why?
|
| Bacteriuria | 1 | 1987 | 102 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2016 | 1725 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 1962 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2009 | 15831 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 744 | 0.020 |
Why?
|
| Receptors, Complement | 1 | 1987 | 254 | 0.020 |
Why?
|
| Health Promotion | 2 | 1997 | 2209 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 968 | 0.020 |
Why?
|
| Inpatients | 1 | 2018 | 2566 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2012 | 854 | 0.020 |
Why?
|
| Osteosclerosis | 1 | 2006 | 41 | 0.020 |
Why?
|
| Urination Disorders | 1 | 1987 | 236 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 2669 | 0.020 |
Why?
|
| Neutrophils | 2 | 1991 | 3782 | 0.020 |
Why?
|
| Hematuria | 1 | 1987 | 232 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1987 | 238 | 0.020 |
Why?
|
| gamma-Globulins | 1 | 1985 | 119 | 0.020 |
Why?
|
| Physical Fitness | 2 | 2002 | 743 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2131 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2007 | 299 | 0.020 |
Why?
|
| Cephalosporins | 1 | 1986 | 200 | 0.020 |
Why?
|
| Adiponectin | 1 | 2011 | 1121 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 1775 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 3951 | 0.020 |
Why?
|
| Health Behavior | 1 | 1997 | 2649 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 4114 | 0.020 |
Why?
|
| Cell Line | 2 | 2014 | 15564 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3600 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3427 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 4047 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 874 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 1900 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2011 | 2085 | 0.010 |
Why?
|
| Syphilis | 1 | 1987 | 243 | 0.010 |
Why?
|
| Canada | 1 | 2010 | 2126 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2085 | 0.010 |
Why?
|
| Blepharoptosis | 1 | 1986 | 144 | 0.010 |
Why?
|
| Sunlight | 1 | 2006 | 336 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2012 | 2201 | 0.010 |
Why?
|
| Social Support | 1 | 1994 | 2191 | 0.010 |
Why?
|
| Proteinuria | 1 | 1987 | 613 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2011 | 2721 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 915 | 0.010 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 1549 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2018 | 3989 | 0.010 |
Why?
|
| Streptococcus agalactiae | 1 | 1985 | 337 | 0.010 |
Why?
|
| International Cooperation | 1 | 2010 | 1434 | 0.010 |
Why?
|
| Macrophages | 3 | 1987 | 5784 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1987 | 537 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1991 | 2931 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2007 | 1251 | 0.010 |
Why?
|
| Telemedicine | 1 | 2021 | 3111 | 0.010 |
Why?
|
| Phagocytosis | 2 | 1987 | 1526 | 0.010 |
Why?
|
| Blood Glucose | 2 | 2012 | 6422 | 0.010 |
Why?
|
| Cataract | 1 | 1989 | 837 | 0.010 |
Why?
|
| Hippocampus | 1 | 2015 | 3776 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 22350 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2016 | 3466 | 0.010 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 18329 | 0.010 |
Why?
|
| Absorption | 1 | 2002 | 242 | 0.010 |
Why?
|
| Fibronectins | 1 | 1985 | 722 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 1996 | 2884 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 4050 | 0.010 |
Why?
|
| Binding Sites | 1 | 2010 | 6013 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 2234 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 3837 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 387 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2001 | 365 | 0.010 |
Why?
|
| Digestive System | 1 | 2002 | 244 | 0.010 |
Why?
|
| Insulin | 2 | 2012 | 6608 | 0.010 |
Why?
|
| Primary Health Care | 2 | 2003 | 4735 | 0.010 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2001 | 136 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2887 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 2902 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 2001 | 3053 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8734 | 0.010 |
Why?
|
| Time | 1 | 2002 | 550 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2007 | 1852 | 0.010 |
Why?
|
| Family Practice | 1 | 2003 | 508 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 11094 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3803 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2002 | 559 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2000 | 135 | 0.010 |
Why?
|
| New England | 1 | 2003 | 1058 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 684 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7841 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2012 | 3957 | 0.010 |
Why?
|
| Glucagon | 1 | 2001 | 534 | 0.010 |
Why?
|
| Sporothrix | 1 | 1978 | 3 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2018 | 26387 | 0.010 |
Why?
|
| Mitosporic Fungi | 1 | 1978 | 17 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8728 | 0.010 |
Why?
|
| Nasal Cavity | 1 | 2000 | 310 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 21162 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2000 | 828 | 0.010 |
Why?
|
| Ascomycota | 1 | 1978 | 82 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 2392 | 0.010 |
Why?
|
| Brain | 1 | 2024 | 27158 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 1887 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1989 | 4525 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2001 | 1472 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1978 | 826 | 0.010 |
Why?
|
| Lipids | 1 | 2007 | 3322 | 0.010 |
Why?
|
| Monocytes | 1 | 1985 | 2599 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1991 | 4858 | 0.010 |
Why?
|
| Fees and Charges | 1 | 1996 | 189 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 36459 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 1469 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 7119 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 1993 | 7870 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1987 | 3114 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 36570 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 5098 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 1606 | 0.010 |
Why?
|
| Dogs | 2 | 1987 | 3834 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1997 | 3468 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 1203 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1997 | 3618 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 30214 | 0.010 |
Why?
|
| Reaction Time | 1 | 1997 | 2085 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 8108 | 0.010 |
Why?
|
| Cell Division | 1 | 1997 | 4473 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 3618 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8540 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 6225 | 0.000 |
Why?
|
| Staphylococcus aureus | 2 | 1986 | 1429 | 0.000 |
Why?
|
| Health Education | 1 | 1995 | 1060 | 0.000 |
Why?
|
| Peritoneal Cavity | 1 | 1987 | 135 | 0.000 |
Why?
|
| Haemophilus influenzae | 1 | 1986 | 177 | 0.000 |
Why?
|
| Hospitals, Teaching | 1 | 1990 | 1156 | 0.000 |
Why?
|
| Rats | 1 | 2001 | 23717 | 0.000 |
Why?
|
| Macrophage Activation | 1 | 1987 | 554 | 0.000 |
Why?
|
| Endotoxins | 1 | 1986 | 519 | 0.000 |
Why?
|
| Cricetinae | 1 | 1987 | 2416 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1987 | 1606 | 0.000 |
Why?
|
| Hydrogen Peroxide | 1 | 1986 | 741 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 2551 | 0.000 |
Why?
|
| Biological Transport | 1 | 1986 | 2083 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1987 | 3093 | 0.000 |
Why?
|
| Shock, Septic | 1 | 1986 | 772 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1986 | 1972 | 0.000 |
Why?
|
| Rhamnose | 1 | 1978 | 18 | 0.000 |
Why?
|
| Immunodiffusion | 1 | 1978 | 141 | 0.000 |
Why?
|
| Kinetics | 1 | 1986 | 6288 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1985 | 1367 | 0.000 |
Why?
|
| Mannose | 1 | 1978 | 121 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1978 | 816 | 0.000 |
Why?
|
| Cell Survival | 1 | 1986 | 5749 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1986 | 4211 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 13489 | 0.000 |
Why?
|
| Rabbits | 1 | 1978 | 4752 | 0.000 |
Why?
|
| Pregnancy | 1 | 1985 | 30236 | 0.000 |
Why?
|